Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA.

Br J Cancer. 2018 Oct 15. doi: 10.1038/s41416-018-0290-8. [Epub ahead of print]

PMID:
30318518
2.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2018 Nov;82(5):757-766. doi: 10.1007/s00280-018-3661-1. Epub 2018 Aug 7.

PMID:
30088048
3.

Targeting gamma secretase: has progress moved up a Notch?

Ileana Dumbrava EE, Mills GB, Yap TA.

Ann Oncol. 2018 Sep 1;29(9):1889-1891. doi: 10.1093/annonc/mdy307. No abstract available.

PMID:
30084907
4.

Combination drug development in BRAF mutant colorectal cancer.

Lam M, Pant S, Yap TA.

Oncoscience. 2018 Apr 29;5(3-4):51-53. doi: 10.18632/oncoscience.399. eCollection 2018 Mar. No abstract available.

5.

Challenges with biomarkers in cancer drug discovery and development.

Ileana Dumbrava E, Meric-Bernstam F, Yap TA.

Expert Opin Drug Discov. 2018 Aug;13(8):685-690. doi: 10.1080/17460441.2018.1479740. Epub 2018 May 24. No abstract available.

PMID:
29792354
6.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
7.

Introduced bullfrog facilitates pathogen invasion in the western United States.

Yap TA, Koo MS, Ambrose RF, Vredenburg VT.

PLoS One. 2018 Apr 16;13(4):e0188384. doi: 10.1371/journal.pone.0188384. eCollection 2018.

8.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

PMID:
29533782
9.

Targeting the PI3K pathway in cancer: are we making headway?

Janku F, Yap TA, Meric-Bernstam F.

Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6. Review.

PMID:
29508857
10.

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.

Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2. Review.

PMID:
29420224
11.

Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword.

Tang C, Jiang W, Yap TA.

JAMA Oncol. 2018 Aug 1;4(8):1116-1117. doi: 10.1001/jamaoncol.2017.4606. No abstract available.

PMID:
29327039
12.

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.

Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.

13.

Precision oncology: East meets West.

Subbiah V, Rodon J, Yap TA.

Int J Cancer. 2018 May 1;142(9):1734-1737. doi: 10.1002/ijc.31218. Epub 2018 Jan 4. No abstract available.

PMID:
29243227
14.

Precision Medicine: Progress, Pitfalls, and Promises.

Pilié PG, LoRusso PM, Yap TA.

Mol Cancer Ther. 2017 Dec;16(12):2641-2644. doi: 10.1158/1535-7163.MCT-17-0904. No abstract available.

PMID:
29203693
15.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R.

J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26.

PMID:
29178442
16.

Batrachochytrium salamandrivorans and the Risk of a Second Amphibian Pandemic.

Yap TA, Nguyen NT, Serr M, Shepack A, Vredenburg VT.

Ecohealth. 2017 Dec;14(4):851-864. doi: 10.1007/s10393-017-1278-1. Epub 2017 Nov 16. Review.

PMID:
29147975
17.

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.

PMID:
29093017
18.

Development of Molecularly Driven Targeted Combination Strategies.

Yap TA, Rodon J.

Oncologist. 2017 Dec;22(12):1421-1423. doi: 10.1634/theoncologist.2017-0402. Epub 2017 Oct 16. No abstract available.

19.

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U.

PLoS One. 2017 Oct 5;12(10):e0186106. doi: 10.1371/journal.pone.0186106. eCollection 2017.

20.

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA.

Lung Cancer. 2017 Sep;111:6-11. doi: 10.1016/j.lungcan.2017.06.005. Epub 2017 Jun 15.

21.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
22.

Targeting ATR in cancer medicine.

Sundar R, Brown J, Ingles Russo A, Yap TA.

Curr Probl Cancer. 2017 Jul - Aug;41(4):302-315. doi: 10.1016/j.currproblcancer.2017.05.002. Epub 2017 May 17. Review.

PMID:
28662958
23.

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

Sundar R, Hong DS, Kopetz S, Yap TA.

Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087.

24.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

25.

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Sundar R, Chénard-Poirier M, Collins DC, Yap TA.

Front Med (Lausanne). 2017 Apr 10;4:39. doi: 10.3389/fmed.2017.00039. eCollection 2017. Review.

26.

Circulating tumor DNA-From bench to bedside.

Lim JSJ, Janku F, Yap TA.

Curr Probl Cancer. 2017 May - Jun;41(3):212-221. doi: 10.1016/j.currproblcancer.2017.02.005. Epub 2017 Mar 1.

PMID:
28416241
27.

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA.

Drugs. 2017 May;77(8):813-827. doi: 10.1007/s40265-017-0732-2. Review.

PMID:
28378229
28.

Precision medicine in oncology.

Takebe N, Yap TA.

Curr Probl Cancer. 2017 May - Jun;41(3):163-165. doi: 10.1016/j.currproblcancer.2017.01.001. Epub 2017 Jan 24. No abstract available.

PMID:
28372822
29.

Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging.

Winfield JM, Tunariu N, Rata M, Miyazaki K, Jerome NP, Germuska M, Blackledge MD, Collins DJ, de Bono JS, Yap TA, deSouza NM, Doran SJ, Koh DM, Leach MO, Messiou C, Orton MR.

Radiology. 2017 Jul;284(1):88-99. doi: 10.1148/radiol.2017161965. Epub 2017 Mar 16.

30.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.

Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.

PMID:
28273485
31.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
32.

Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.

Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA.

Curr Probl Cancer. 2017 Mar - Apr;41(2):111-124. doi: 10.1016/j.currproblcancer.2016.12.002. Epub 2016 Dec 23. Review.

PMID:
28214087
33.

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

Brown JS, O'Carrigan B, Jackson SP, Yap TA.

Cancer Discov. 2017 Jan;7(1):20-37. doi: 10.1158/2159-8290.CD-16-0860. Epub 2016 Dec 21. Review.

34.

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

Yap TA, Popat S.

J Thorac Oncol. 2017 Jan;12(1):12-14. doi: 10.1016/j.jtho.2016.10.019. No abstract available.

35.

Emerging biomarkers for PD-1 pathway cancer therapy.

Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA.

Biomark Med. 2017 Jan;11(1):53-67. Epub 2016 Dec 12. Review.

PMID:
27936870
36.

Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.

Collins DC, Sundar R, Lim JSJ, Yap TA.

Trends Pharmacol Sci. 2017 Jan;38(1):25-40. doi: 10.1016/j.tips.2016.10.012. Epub 2016 Nov 18. Review.

PMID:
27871777
37.

Emerging strategies for the treatment of advanced small cell lung cancer.

Lim JS, Collins D, Yap TA.

J Thorac Dis. 2016 Oct;8(10):E1249-E1253. No abstract available.

38.

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.

Yap TA, Macklin-Doherty A, Popat S.

Eur J Cancer. 2017 Jan;70:12-21. doi: 10.1016/j.ejca.2016.10.014. Epub 2016 Nov 17. Review.

PMID:
27866095
39.

Combining Molecularly Targeted Agents: Is More Always Better?

Sundar R, Valeri N, Harrington KJ, Yap TA.

Clin Cancer Res. 2017 Mar 1;23(5):1123-1125. doi: 10.1158/1078-0432.CCR-16-2399. Epub 2016 Nov 10.

40.

A study of motivations and expectations of patients seen in phase 1 oncology clinics.

Dolly SO, Kalaitzaki E, Puglisi M, Stimpson S, Hanwell J, Fandos SS, Stapleton S, Ansari T, Peckitt C, Kaye S, Lopez J, Yap TA, van der Graaf W, de Bono J, Banerji U.

Cancer. 2016 Nov 15;122(22):3501-3508. doi: 10.1002/cncr.30235. Epub 2016 Sep 26.

41.

Immuno-oncology combinations: raising the tail of the survival curve.

Harris SJ, Brown J, Lopez J, Yap TA.

Cancer Biol Med. 2016 Jun;13(2):171-93. doi: 10.20892/j.issn.2095-3941.2016.0015.

42.

Drug discovery in advanced prostate cancer: translating biology into therapy.

Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS.

Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22. Review.

PMID:
27444228
43.

CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.

Lim JS, Turner NC, Yap TA.

Cancer Discov. 2016 Jul;6(7):697-9. doi: 10.1158/2159-8290.CD-16-0563.

44.

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development.

Yap TA, Banerji U, de Bono JS, Workman P.

J Clin Oncol. 2016 Jul 10;34(20):2431-2. doi: 10.1200/JCO.2016.67.0075. Epub 2016 May 2. No abstract available.

PMID:
27138581
45.

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

Puglisi M, Stewart A, Thavasu P, Frow M, Carreira S, Minchom A, Punwani R, Bhosle J, Popat S, Ratoff J, de Bono J, Yap TA, O''Brien M, Banerji U.

Oncology. 2016;90(5):280-8. doi: 10.1159/000444928. Epub 2016 Apr 16.

PMID:
27082424
46.

Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

Sharp A, Bhosle J, Abdelraouf F, Popat S, O'Brien M, Yap TA.

Eur J Cancer. 2016 Jun;60:26-39. doi: 10.1016/j.ejca.2016.03.004. Epub 2016 Apr 7. Review.

PMID:
27060747
47.

PARP inhibitors: the race is on.

Brown JS, Kaye SB, Yap TA.

Br J Cancer. 2016 Mar 29;114(7):713-5. doi: 10.1038/bjc.2016.67. No abstract available.

48.

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.

Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, Yap TA, Du Y, Vlahos I, deSouza NM.

Eur J Cancer. 2016 May;59:65-78. doi: 10.1016/j.ejca.2016.02.017. Epub 2016 Mar 24. Review.

PMID:
27016624
49.

Phase I trial outcomes in older patients with advanced solid tumours.

Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB.

Br J Cancer. 2016 Feb 2;114(3):262-8. doi: 10.1038/bjc.2015.477. Epub 2016 Jan 12.

50.

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.

Kumar R, Lu SK, Minchom A, Sharp A, Davidson M, Gunapala R, Yap TA, Bhosle J, Popat S, O'Brien ME.

Cancer Chemother Pharmacol. 2016 Feb;77(2):375-83. doi: 10.1007/s00280-015-2950-1. Epub 2015 Dec 26.

PMID:
26706729

Supplemental Content

Support Center